TP53 and neuroblastoma: To evaluate the in vivo antitumor activity of CGM097 against TP53 wild-type neuroblastoma tumors that harbor wild-type ALK or ALK aberrations, we treated xenografts derived from ALK-amplified NB-1 cells, F1174L-mutated SH-SY5Y cells, R1275Q-mutated NB-1643 cells and ALK wild-type IMR-32 cells.